Skip to main content

Table 4 Disutility, incremental mortality, and costs for the first year and subsequent years after fracture and diabetes

From: Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada

 

Fracture

Diabetes

Age

1st year

Subsequent years

1st year

Subsequent years

Disutility by age group

40-44

-0.0833

-0.0293

-0.000179

-0.000333

45-49

-0.0971

-0.0324

-0.000173

-0.000247

50-54

-0.1047

-0.0349

-0.000160

-0.000263

55-59

-0.1068

-0.0371

-0.000074

-0.000681

60-64

-0.1094

-0.0391

-0.000040

-0.000727

65-69

-0.1113

-0.0412

-0.000003

-0.000618

70+

-0.1212

-0.0425

-0.000128

-0.000754

Incremental mortality by age group

40-44

0.0092

0.0001

0.000390

0.000320

45-49

0.0115

0.0001

0.000715

0.000285

50-54

0.0127

0.0001

0.000875

0.000685

55-59

0.0142

0.0002

0.001160

0.000320

60-64

0.0187

0.0003

0.001525

0.000755

65-69

0.0260

0.0006

0.002025

0.001035

70+

0.0541

0.0018

0.002645

0.000850

Costs by age group

40-44

$3,926

$63

$12

$24

45-49

$4,643

$68

$13

$32

50-54

$5,041

$73

$16

$55

55-59

$5,159

$78

$21

$93

60-64

$5,302

$83

$24

$151

65-69

$7,901

$87

$25

$260

70+

$10,880

$744

$27

$341